Extension for Community Healthcare Outcomes (ECHO) Autism Diagnostic Study in Primary Care Setting

Last updated: February 6, 2024
Sponsor: Cognoa, Inc.
Overall Status: Completed

Phase

N/A

Condition

Autism

Asperger's Disorder

Williams Syndrome

Treatment

Canvas Dx

Clinical Study ID

NCT05223374
2075722
  • Ages 18-72
  • All Genders

Study Summary

This is a collaborative study that will provide a comprehensive source of observational data that can be used to obtain real world evidence of ASD. The study will contain demographic and observational clinical data for eligible participants. All decisions regarding patient care will be determined by the ECHO Autism Clinician (EAC). All clinical outcomes will be assessed by the EAC as would occur in routine clinical practice.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. English is spoken proficiently by the participating patient/family, in the opinion ofthe EAC.
  2. Meets labeling of device
  3. Parent, guardian, or legally authorized representative (LAR) must be able to read,understand, and sign and date the Informed Consent Form (ICF)
  4. Sex assigned at birth (Female or male or non-binary)
  5. Female or male, > 18 to < 72 months of age
  6. Caregiver, HCP or community-based professional concern for developmental delay orAutism
  7. Parent/guardian/LAR must have smartphone utilizing the most recent and previousversion of iOS and Android operating systems (iOS 13 or 14; Android 10 or 11,excluding Android Go)
  8. Participants must be willing to be videotaped as part of the device input

Exclusion

Exclusion Criteria:

  1. Participants with a prior diagnosis of Autism Spectrum Disorder (ASD) rendered by ahealthcare professional
  2. Participants with any other medical, behavioral, or developmental condition that inthe opinion of the ECHO Autism Clinician may confound study data/assessments
  3. Participants whose age on the date of enrollment is outside the target age range
  4. Participants or caregivers who have, to the best of their knowledge, been previouslyenrolled in any Cognoa clinical study or survey

Study Design

Total Participants: 110
Treatment Group(s): 1
Primary Treatment: Canvas Dx
Phase:
Study Start date:
March 01, 2022
Estimated Completion Date:
February 04, 2024

Study Description

The study will be conducted by the University of Missouri ECHO Autism Communities Research Team (RT). Research participants recruited by the RT will include: 1) University of Missouri ECHO Autism Community trained clinicians (EACs) in both rural and suburban areas across the United States; 2)Caregivers/Patients with a suspicion of autism. Caregivers/Patients with a suspicion of autism and EACs will complete the informed consent process prior to entering the study. Once enrolled, EACs will provide routine clinical care and conduct best-practice ECHO Autism diagnostic evaluations with the addition of Canvas Dx to patients who have a suspicion of autism spectrum disorder. Canvas Dx will be prescribed; the caregiver will download and access the diagnostic app with a code. The caregiver will then complete the following activities:

  • Complete Caregiver Questionnaire in the mobile app

  • Upload two 90 sec to 5-minute videos of the participant through the mobile app

Connect with a study center

  • ECHO Autism

    Columbia, Missouri 65201
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.